Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children

Influenza Clinical Trial

Official title:

Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00884182
• Other study ID #: GPA12
• Status: Completed
• Phase: Phase 2
• First received: April 16, 2009
• Last updated: January 10, 2014
• Start date: April 2009
• Est. completion date: June 2010

Study information

• Verified date: January 2014
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Finnish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic.

Study objectives:

• To describe the safety profiles in the periods following each vaccination in subjects receiving different vaccination schedule.

• To describe the immune response after each vaccination in subjects receiving study vaccine.

Description:

Study participants will receive two administrations of the investigational vaccine at one of 3 vaccination schedules.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 350
• Est. completion date: June 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 6 Months to 17 Years

Eligibility

Inclusion Criteria :

All Subjects

• Subject and parent(s)/legal representative able to attend all scheduled visits and to comply with all trial procedures.

• Completion of vaccination according to the national immunization schedule

Subjects Aged = 2 Years to < 18 Years:

• Aged = 2 years to < 18 years on the day of inclusion.

• Provision of Informed Consent Form signed by the subject's the parent(s)/legal representative (and by an independent witness if required by local regulations). In addition, provision of Assent Form signed by subjects aged 8 to 11 years, and of Informed Consent Form signed by subjects = 12 years.

• For a female of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to each vaccination, until at least 4 weeks after each vaccination.

Subjects Aged = 6 Months to < 2 Years:

• Aged = 6 months to < 2 years on the day of inclusion.

• Born at full term of pregnancy (= 37 weeks) with a birth weight = 2.5 kg.

• Provision of Informed Consent Form signed by the parent(s) or other legal representative (and by an independent witness if required by local regulations).

Exclusion Criteria :

All subjects

• Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding trial vaccination

• Planned participation in another clinical trial during the present trial period

• Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy

• Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances

• Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator

• Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures

• Receipt of Blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response

• Receipt of any vaccine in the 4 weeks preceding trial vaccination

• Planned receipt of any vaccine in the 4 weeks following any trial vaccination

• (Known) Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen or Hepatitis C seropositivity

• Previous vaccination against avian influenza with either the trial vaccine or another vaccine

• Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination

• Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent

• Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw

Subjects Aged =2 Years to <18 Years:

• For a female of child-bearing potential, known pregnancy or positive urine pregnancy test

• Breast-feeding female

• Febrile illness (temperature = 37.5 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment

Subjects Aged = 6 Months to < 2 Years:

• History of seizures

• Febrile illness (temperature = 38 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Infection
• Influenza
• Influenza, Human
• Orthomyxoviridae Infections
• Orthomyxovirus Infections

Intervention

Biological:
• A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
0.5 mL, Intramuscular

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To provide information concerning the safety of the Split Virion Pandemic Influenza vaccine.		21 days post-vaccination and entire study	Yes
Secondary	To provide information concerning the immunogenicity of Split Virion Pandemic Influenza vaccine.		21 days post-vaccination	No

External Links

•   Link
•   Link